Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...

Diabetic Nephropathy

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Personalizing Cardio-Kidney-Metabolic Therapy: Closer But Not There Yet.

Journal of the American Society of Nephrology : JASN·2026

Same author

Atrial Fibrillation and Stroke Prevention and Management in Chronic Kidney Disease.

Clinical journal of the American Society of Nephrology : CJASN·2026

Same author

Cannabis Use among People Receiving Maintenance Hemodialysis with Chronic Pain.

Kidney360·2026

Same author

Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial.

ESC heart failure·2026

Same author

Cardiac-Gated Diffusion-Weighted Magnetic Resonance Imaging Assessment of Kidney Function in Patients With Kidney Cancer.

Kidney international reports·2026

Same author

A Pilot Randomized Controlled Trial of Integrated Nephrology and Palliative Care Implemented at a Safety-Net Hospital.

Kidney medicine·2026

Search research articles

Related Experiment Video

Updated: May 29, 2026

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

Circulating endoglin concentration is not elevated in chronic kidney disease.

David M Charytan¹, Alexander M Helfand, Brian A MacDonald

¹Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America. dcharytan@partners.org

|September 3, 2011

Summary

Circulating soluble endoglin levels do not change with chronic kidney disease (CKD) severity. Therefore, soluble endoglin is unlikely to be a factor in CKD progression or cardiovascular disease risk in these patients.

More Related Videos

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Related Experiment Videos

Last Updated: May 29, 2026

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Area of Science:

Cardiovascular Physiology
Nephrology
Biomarker Research

Background:

Soluble endoglin, a transforming growth factor-beta (TGF-β) receptor, is crucial for cardiovascular health.
The relationship between soluble endoglin levels and chronic kidney disease (CKD) remains unclear.
It is unknown if elevated soluble endoglin contributes to cardiovascular mortality in CKD patients.

Purpose of the Study:

To investigate the association between circulating soluble endoglin concentrations and the presence and stage of CKD.
To determine if soluble endoglin levels are elevated in individuals with CKD.
To assess the potential role of soluble endoglin in CKD progression and associated cardiovascular risks.

Main Methods:

Serum endoglin levels were measured in 216 participants (118 with CKD stage 3+).
Estimated glomerular filtration rate (eGFR) and CKD stage were determined.
Univariate and multivariable regression analyses examined the association between eGFR, CKD stage, and soluble endoglin concentration.

Main Results:

Serum endoglin concentration did not significantly correlate with CKD stage (P=0.09) or eGFR (P=0.12).
Endoglin levels were similar in patients with end-stage renal disease (ESRD) and those with preserved renal function.
No significant association was found between endoglin concentration and urinary albumin excretion.

Conclusions:

Circulating soluble endoglin levels are not associated with renal function in patients.
Elevated soluble endoglin is unlikely to drive CKD progression.
Soluble endoglin does not appear to contribute to the heightened cardiovascular disease risk observed in individuals with CKD.